13F Holdings
中文EN

CRMD CorMedix Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1410098 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY96.3%
TTM net income YoY-60.7%
TTM EPS YoY-71.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin77.0%
Operating margin38.3%
Net margin15.4%
FCF margin74.1%
EBITDA margin46.0%

Returns

ROE15.3%
ROA7.7%
ROIC (approx.)27.3%
Asset turnover0.50x

Leverage & solvency

Liabilities / assets49.7%
Debt / equity0.00x
Current ratio2.43x
Interest coverage—

Cash quality & payout

Operating cash flow / net income4.90x
Accruals ratio-29.8%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$311.71M$43.47M—$65,408$190,936
Cost of revenue$22.09M$3.03M—$3,734$148,938
Gross profit$275.75M$40.28M—$61,674$41,998
R&D expense$19.33M$3.94M$13.16M$10.68M$13.13M
SG&A expense$68.22M$29.96M$17.69M$20.01M$16.35M
Operating income$150.14M-$22.36M-$48.96M-$30.62M-$29.44M
Interest expense$2.78M$36,000$34,296$26,515$15,943
Pretax income$150.02M-$19.32M-$46.34M-$29.97M-$29.46M
Income tax-$13.04M-$1.40M—-$585,617-$1.25M
Net income$163.06M-$17.93M-$46.34M-$29.70M-$28.21M
EBITDA$150.82M-$22.20M-$48.89M-$30.54M-$29.38M
EPS (basic)2.25-0.30-0.91-0.74-0.75
EPS (diluted)2.04-0.30-0.91-0.74-0.75
Weighted avg. shares (diluted)80,30858,87250.90M40.27M37.67M
Banking
Net interest income—$1.40M———
Balance sheet
Cash & equivalents$144.84M$40.76M$43.82M$43.37M$53.55M
Short-term investments$3.69M$11.04M$32.39M$15.64M$12.15M
Receivables$171.23M$51.65M———
Inventory$29.72M$7.60M$2.11M—$3,008
Current assets$367.05M$114.58M$79.45M$59.55M$66.47M
PP&E, net$5.96M$1.83M$1.87M$1.61M$1.47M
Goodwill$30.00M————
Intangibles$379.07M$1.84M———
Total assets$826.14M$118.85M$82.06M$62.04M$68.95M
Current liabilities$174.27M$33.84M$11.40M$6.31M$5.35M
Long-term debt$150,000————
Total debt$150,000————
Total liabilities$420.83M$34.19M$11.92M$6.98M$6.15M
Shareholders' equity$405.31M$84.66M$70.14M$55.06M$62.80M
Net debt-$144.69M————
Shares outstanding79.26M64.41M54.94M42.82M38.09M
Cash flow statement
Operating cash flow$175.05M-$50.62M-$38.41M-$24.36M-$21.16M
Capital expenditure$2.26M$116,000$327,300$219,360$1.43M
Free cash flow$172.79M-$50.73M-$38.74M-$24.58M-$22.58M
Investing cash flow-$308.43M$21.23M-$17.06M-$3.71M-$9.13M
Financing cash flow$238.45M$26.32M$55.92M$17.90M$41.76M
Depreciation & amortization$677,000$154,000$70,755$84,618$61,890
Stock-based compensation$13.83M$6.13M$5.49M$4.07M$5.04M

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.